Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced the acceptance of four abstracts for presentation at The Liver Meeting (TLM) 2024, hosted by the American Association for the Study of Liver Disease (AASLD) from November 15-19, 2024 in San Diego. The presentations include:

1. A late-breaker oral presentation on ALG-055009, a potential best-in-class THR-β agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), showcasing Phase 2a HERALD study results.

2. Three poster presentations: two on ALG-000184, a potential first-/best-in-class CAM-E for chronic hepatitis B (CHB), and one on the nonclinical toxicology profile of ALG-055009.

The abstracts highlight promising results for both drug candidates, including high viral suppression rates for ALG-000184 in CHB patients and significant liver fat reductions for ALG-055009 in MASH patients.

Positive

• Four abstracts accepted for presentation at The Liver Meeting 2024, including a late-breaker oral presentation
• ALG-000184 shows high viral suppression rates in untreated HBeAg+ and HBeAg- subjects with chronic hepatitis B
• ALG-055009 demonstrates significant reductions in liver fat at Week 12 in non-cirrhotic MASH patients
• Both ALG-000184 and ALG-055009 are potential best-in-class therapies for their respective indications

Negative

• None.

Insights

Medical Research Analyst

This news highlights significant progress in Aligos Therapeutics' clinical pipeline, particularly for their chronic hepatitis B (CHB) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) programs. The acceptance of multiple abstracts at The Liver Meeting 2024 is a positive development, especially the late-breaker oral presentation for ALG-055009 in MASH patients.

Key points:

• ALG-000184 for CHB shows promising results with "high viral suppression rates" in both HBeAg+ and HBeAg- subjects.
• ALG-055009 for MASH demonstrates significant reductions in liver fat at Week 12, which could be a important efficacy indicator.
• The presentation of nonclinical toxicology data for ALG-055009 suggests a comprehensive approach to safety assessment.

While these results are encouraging, it's important to note that this is still early-stage data. The market's reaction will depend on the detailed results presented at the conference, particularly the magnitude of liver fat reduction and safety profile of ALG-055009. For a small-cap biotech like Aligos ($22.8M market cap), positive data could significantly impact investor sentiment and potentially lead to partnership opportunities or increased funding interest.

Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced four abstracts have been accepted, including one late-breaker oral presentation and three poster presentations, at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting. Late-breaker abstracts will be available on November 15, 2024.

Details on the abstracts are as follows:

ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B (CHB)

Abstract #: 1213
Title: Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 15, 2024, 8:00am – 5:00pm PT

Abstract #: 1266
Title: Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro
Presenter: Cheng Liu, PhD
Date/Time: November 15, 2024, 8:00am – 5:00pm PT

ALG-055009: Potential best-in-class small molecule THR-β for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Format: Oral presentation
Title: ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
Presenter: Rohit Loomba, MD, MHSc, Chief, Division of Gastroenterology and Hepatology, University of California, San Diego
Date/Time: November 19, 2024 at 10:30am – 10:40am PT

Abstract #: 3226
Title: Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Presenter: Dinah Misner, PhD
Date/Time: November 17, 2024, 8:00am – 5:00pm PT

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.  

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com

FAQ

What are the key findings for ALG-000184 in chronic hepatitis B patients presented at The Liver Meeting 2024?

ALG-000184, a capsid assembly modulator, demonstrated high viral suppression rates in untreated HBeAg+ and HBeAg- subjects with chronic hepatitis B or chronic hepatitis B virus infection. The study also showed that capsid assembly modulators like ALG-001075 induce profound HBV DNA knockdown and directly target HBeAg in vitro.

What results did Aligos Therapeutics (ALGS) report for ALG-055009 in MASH patients at AASLD's The Liver Meeting 2024?

Aligos Therapeutics reported that ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist, was well-tolerated and showed significant reductions in liver fat at Week 12 in non-cirrhotic MASH patients. These results were from the ongoing randomized, double-blind, placebo-controlled Phase 2 HERALD study.

How many abstracts did Aligos Therapeutics (ALGS) have accepted for The Liver Meeting 2024?

Aligos Therapeutics had four abstracts accepted for The Liver Meeting 2024, including one late-breaker oral presentation and three poster presentations. These abstracts cover their drug candidates ALG-000184 for chronic hepatitis B and ALG-055009 for MASH.

When and where will Aligos Therapeutics (ALGS) present its research at The Liver Meeting 2024?

Aligos Therapeutics will present its research at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), from November 15-19, 2024 in San Diego, CA. The presentations include poster sessions and a late-breaker oral presentation.